In this episode, John Gagliano and Sheff discuss the latest trends in the biotech market, focusing on key companies, earnings season insights, and upcoming catalysts. They highlight the importance of FDA communications and breakthrough designations, as well as the impact of recent data releases on stock performance. The conversation also touches on charity work and includes a brief interview with Billy Henry, the Founder of an organization that helps the visually impaired.

In this episode:
🔹Viking Therapeutics has faced challenges with recent data releases.
🔹 How Breakthrough designations can enhance a company's market position.
🔹 The FDA's communication with companies has improved, leading to faster decisions.

Sheff is proud to support the Northwest Association for Blind Athletes. Join us in empowering life-changing opportunities for visually impaired youth and adults through sports and community engagement. You can support this as well in the link below:
Support NWABA: https://nwaba.org/support/other-ways-to-help/sheffstation/#join-sheff-station

🧭 Track upcoming catalysts: https://www.biopharmcatalyst.com/calendars/fda-calendar
🎧 Listen to more episodes: https://www.biopharmcatalyst.com/podcast
📈 See Sheff’s Watchlist: https://www.biopharmcatalyst.com/sheffs-trades

📲 Follow BioPharmCatalyst: https://x.com/BPharmCatalyst
📲 Follow Sheff: https://x.com/SheffStation

Disclaimer: BioPharmCatalyst is not a registered investment advisory firm and the views on this podcast are not to intended to be financial advice. The stocks discussed in this podcast may be held in personal or other investment accounts. This content is for informational purposes only and should not be considered investment advice. Always do your own research before making any investment decisions.